There is significant interest in coenzyme Q 10 (CoQ 10 ) as a potential treatment for neurodegenerative diseases and in its promise as a neuroprotectant. Experimental studies indicate that CoQ 10 can protect against brain disorders by inhibiting neuronal damage. There is a need to demonstrate CSF levels of CoQ 10 in humans.
INTRODUCTION
Coenzyme Q 10 (CoQ 10 ), a lipid component of virtually all cell membranes, has several important biological functions. In the mitochondria, CoQ 10 transfers electrons from complex I and complex II to complex III of respiratory chain. It is also an antioxidant [1] , a membrane stabilizer [2] , and in adipose tissues, it serves as a cofactor for uncoupling proteins [3] .
CoQ 10 deficiency has been observed in patients with Parkinsons disease, Huntington,s disease, tuberous sclerosis, motor neuron disease, and cerebellar ataxia, CoQ 10 supplementation may be useful in these conditions [4] [5] [6] [7] . CoQ 10 deficiency has also been observed in patients receiving statins, which is known to cause myopathy and rhabdomyolysis [8] [9] [10] . Coenzyme CoQ 10 administration increases,brain mitochondrial concentrations and exerts neuroprotectie effects [11, 12] . CoQ 10 is responsible for energy generation through the mitochondrial respiratory chain and because of its antioxidant properties, indirect support for pathogenetic role of CoQ 10 deficiency is provided from data from patients with idiopathic,primary CoQ 10 deficiency in mitochondrial myopathies [13] [14] [15] . These patients have a mitochondrial encephalomyopathy, most commonly presenting as a autosomal recessive spinocerebellar atrophy syndrome. A rarer myopathic varient combines central nervous system signs; ataxia,epilepsy,and mental retardation,with a mitochondrial myopathy dominated by recurrent rhabdomyolysis and myoglobinuria which are also an adverse effect of statin. A circadian rhythm in the coenzyme concentrations and a histochemical demonstration of a circadian rhythm of succinate dehydrogenase in rat pineal gland, and influence of CoQ 10 addition has also been observed [16] .
Naini and coworkers in 19 new patients with cerebellar ataxia established the existence of an ataxic syndrome due to primary CoQ 10 deficiency and responsive to CoQ 10 treatment [6] . Since all patients presented with cerebellar ataxia and cerebellar atrophy, this poses the possibility of a selective vulnerability of the cerebellam to CoQ 10 deficiency. These workers found that in rats, cerebellum had the lowest level of CoQ 10 and the level of CoQ 10 was much higher in brain than in blood or visceral tissue, such as heart,liver or kidney indicating that it has vital role in brain function and degeneration [6] . However, there is lack of evidence, to demonstrate the cerebrospinal fluid levels of CoQ 10 in normal subjects, compared to neurological degenerative diseases.
SUBJECTS AND METHODS
This is a case control study conducted in the Department of Internal Medicine, Halberg Hospital and Research Institute, Moradabad, India. It has a institutional ethic committee involving experts from other institutions and public. After clearance from the hospital ethic committee, all the subjects presenting with a suspicion of neurological diseases(n=37) were asked to give written informed consent for lumber puncture for testing of CSF. CoQ 10 concentration in CSF was examined by HPLC with electrochemical detection after hexane extraction and purification. Briefly, CSF specimens were centrifuged at 3000 x g and 4 ºC for 15 min and a 2-mL aliquot was subjected to hexane extraction essentially as described by Lang e al. (1986) . The HPLC system consisted of model 582 pump, model 542 autosampler, Coulochem II detector, 5011 Analytical Cell (E1 set at -600 Volts and E2 set at +450 Volts), and 5020 Guard Cell set at +800 Volts and positioned between autosampler and column. All the HPLC system components were from ESA (ESA, Inc., Shelmsford, MA). For the CoQ 10 assay, the extracted CoQ 10 was dissolved in 150 L of 1-propanol and a 50-L portion was directly injected onto the HPLC. The separation was achieved on a C18 reversed-phase column (Waters Corporation, Milford, MA) using a mobile phase containing 50 mM sodium acetate in a mixture of ethanol,methanol, 2-propnol, and acetic acid (50%, 47%, 1.5%, and 1.5% respectively). Data acquisition and processing was performed utilizing EZ chrom HPLC software (Scientific Software Inc., Pleasanton, CA).
Biochemical Method
Clinical and laboratory data were obtained in all the patients (n=38) to confirm the clinical diagnosis. CAT scan head was done in all the patients presenting with seizures and stroke. CSF was examined for cells, sugar and proteins in all the patients.Values were excluded in 5 subjects (11.7 to 26.9 ng/ml) due to possible contamination with blood.
RESULTS
The age varied between 17 to 60 years and the number of males were fewer than females (n=14 vs 19). Patients were suffering from epileptic seizures (n=15), tuberculous meningitis (n=4) and stroke (n=4). Ten patients presented with headache of non-neurological condition with or without fever. The CSF concentration of CoQ 10 was significantly lower among these subjects; mean ± SEM (0.59 ± 0.12,ng/ml), which appears to be normal level of CoQ 10 in healthy subjects. The concentration of CoQ 10 in CSF was greater among patients with TBM (1.27±0.60 ng/ml), seizures (1.26±0.34 ng/ml) and stroke (0.83±0.20 ng/ml) compared to subjects without neurological problem. However, the differences were not significant (ANOVA P>0.05).
DISCUSSION
Here we report data presenting the levels of CoQ 10 in control subjects (subjects with no known neurological abnormalities) and in three groups of patients suffering some form of neurological disorder associated with brain injury. To our knowledge, this is the first report on the levels of CoQ 10 in the CSF in these groups of patients, which compared to serum, is less by about three orders of magnitude. Such low levels of CoQ 10 can only be reliably measured by HPLC with a very sensitive electrochemical detector system. The observation that the subjects, who presented with minimal brain disorders also had the lowest levels of CoQ 10 in their CSF probably indicates that under pathological conditions associated with neurodegeneration, there is a rise in CSF CoQ 10 as a result of either tissue damage and release from the cell or to increased synthesis as a cell response to free radical production caused by injury. In this context, it has recently been shown that increased levels of CoQ10 may protect cells from chemotherapy-induced oxidative stress [17] .
In recent years, the possible beneficial effects of CoQ 10 for the treatment of a wide variety of diseases, including disorders associated with neurodegeneration, has been investigated. In 1999,Singh and Singh used CoQ10 for the treatment of patients with motor neuron disease and polymyositis (18) . However, in most of these studies, CoQ 10 levels were measured in the plasma or the serum and few studies have assessed intracellular CoQ 10 concentration in patients. In the plasma, CoQ 10 is transported with the very low density lipoprotein (VLDL) fraction hence, it's levels are closely related to the plasma VLDL levels which can be affected by both the disease processes and by dietary factors. Moreover, whereas the cellular level of CoQ 10 is dependent mostly on endogenous biosynthesis [18] , the plasma level has been suggested as representing the equilibrium between CoQ 10 absorption and synthesis [19] . Taken together, it appears that the plasma level of CoQ 10 can not always be regarded as a true indicator of cellular levels. Therefore, in studies in which the cellular levels of CoQ 10 and its changes under pathological conditions are investigated, tissues other than serum or plasma are more desirable. In this context, when the role of CoQ 10 in diseases such as Parkinson's disease, Alzimer's disease, Huntuington's disease, or ALS is investigated, CSF is probably a true indicator of cellular level.
In conclusion, this is the first report of CoQ 10 levels in the CSF as measured by highly sensitive HPLC with electrochemical detection system. These preliminary data indicate that (1) the level of CoQ in the CSF is less than in the serum by three orders of magnitude and (2) CSF levels tend to increase after injury. Obviously, with the availability of the methodology, further studies can be conducted to confirm and expand these preliminary findings.
